Form 4: ATAI Life Sciences Director Granted 103,000 Stock Options

ATAI Life Sciences N.V. Director Amir H. Kalali was granted 103,000 stock options with an exercise price of $2.25, vesting by June 26, 2026.

Summary

• Amir H. Kalali, a Director of ATAI Life Sciences N.V. (ATAI), was granted 103,000 stock options.
• The transaction date for this grant was June 26, 2025.
• The exercise price for these stock options is $2.25 per share.
• The options are set to expire on June 26, 2035.
• The stock options will vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 26, 2026.
• Following this transaction, Amir H. Kalali beneficially owns 103,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event, indicating continued alignment of interests between the director and the company's performance. It is a positive signal for governance and incentive alignment, but not a significant market-moving event on its own.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance and shareholder value of ATAI Life Sciences N.V.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of compensation and an incentive to align the interests of the board with those of shareholders. This practice is standard across publicly traded companies to attract and retain qualified board members.

Comparison to Industry Standards

• Granting stock options to directors is a widely accepted compensation method across various industries, including biotech, to incentivize long-term value creation. This aligns with common corporate governance practices seen in companies like Moderna (MRNA) or BioNTech (BNTX), where equity-based compensation is a significant component of executive and director pay.
• The exercise price of $2.25 represents the strike price at the time of grant, which is typical for compensatory option grants, often set at the market price on the grant date.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Amir H. Kalali constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Director (Amir H. Kalali): Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The stock options will vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 26, 2026.
• Upon vesting, the director will have the ability to exercise these options at the specified exercise price of $2.25 per share until the expiration date of June 26, 2035.

Key Dates

Keywords

ATAI Life Sciences, ATAI, Stock Option, Director Compensation, SEC Form 4, Amir H. Kalali, Equity Grant